Melanoma is a significant health problem worldwide, especially in countries with a large, fair-skinned population.
In many Western countries, both the incidence and mortality rates are rising.
Therefore, improved diagnosis and treatment regimens at an early clinical stage are necessary to improve outcome.
Currently, the histological and clinical factors used for diagnosis of melanoma are of limited use.
New biomarkers or gene signatures could provide additional prognostic information based and shed light on the molecular mechanisms of transformation and disease progression.
This is evidenced by the discovery of a significant effect of targeted inhibition of BRAF has on the clinical course of metastatic melanoma.
The Melanoma PCR Primer Library contains a primer sets that amplify putative biomarkers and genes associated with dysregulated signaling in melanoma.